Artificial Intelligence-Enabled Electrocardiography Predicts Left Ventricular Dysfunction and Future Cardiovascular Outcomes: A Retrospective Analysis
Open Access
- 13 March 2022
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (3) , 455
Abstract
BACKGROUND: The ejection fraction (EF) provides critical information about heart failure (HF) and its management. Electrocardiography (ECG) is a noninvasive screening tool for cardiac electrophysiological activities that has been used to detect patients with low EF based on a deep learning model (DLM) trained via large amounts of data. However, no studies have widely investigated its clinical impacts. OBJECTIVE: This study developed a DLM to estimate EF via ECG (ECG-EF). We further investigated the relationship between ECG-EF and echo-based EF (ECHO-EF) and explored their contributions to future cardiovascular adverse events. METHODS: There were 57,206 ECGs with corresponding echocardiograms used to train our DLM. We compared a series of training strategies and selected the best DLM. The architecture of the DLM was based on ECG12Net, developed previously. Next, 10,762 ECGs were used for validation, and another 20,629 ECGs were employed to conduct the accuracy test. The changes between ECG-EF and ECHO-EF were evaluated. The primary follow-up adverse events included future ECHO-EF changes and major adverse cardiovascular events (MACEs). RESULTS: The sex-/age-matching strategy-trained DLM achieved the best area under the curve (AUC) of 0.9472 with a sensitivity of 86.9% and specificity of 89.6% in the follow-up cohort, with a correlation of 0.603 and a mean absolute error of 7.436. In patients with accurate prediction (initial difference < 10%), the change traces of ECG-EF and ECHO-EF were more consistent (R-square = 0.351) than in all patients (R-square = 0.115). Patients with lower ECG-EF (≤35%) exhibited a greater risk of cardiovascular (CV) complications, delayed ECHO-EF recovery, and earlier ECHO-EF deterioration than patients with normal ECG-EF (>50%). Importantly, ECG-EF demonstrated an independent impact on MACEs and all CV adverse outcomes, with better prediction of CV outcomes than ECHO-EF. CONCLUSIONS: The ECG-EF could be used to initially screen asymptomatic left ventricular dysfunction (LVD) and it could also independently contribute to the predictions of future CV adverse events. Although further large-scale studies are warranted, DLM-based ECG-EF could serve as a promising diagnostic supportive and management-guided tool for CV disease prediction and the care of patients with LVD.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (MOST 108-2314-B-016-001, MOST 109-2314-B-016-026, MOST 110-2314-B-016-010-MY3, MOST 108-3111-Y-016-009, MOST 109-3111-Y-016-002, MOST 110-3111-Y-016-005)
This publication has 60 references indexed in Scilit:
- Heart Failure: Preventing Disease and Death WorldwideESC Heart Failure, 2014
- The Global Health and Economic Burden of Hospitalizations for Heart FailureJACC, 2014
- 2013 ACCF/AHA Guideline for the Management of Heart FailureJACC, 2013
- Acute electrocardiographic changes during smoking: an observational studyBMJ Open, 2013
- Abnormal P-wave terminal force in lead V1 is associated with cardiac death or hospitalization for heart failure in prior myocardial infarctionHeart and Vessels, 2012
- Sudden Cardiac Death Caused by Coronary Heart DiseaseCirculation, 2012
- The Role of N-terminal PRO-Brain Natriuretic Peptide and Echocardiography for Screening Asymptomatic Left Ventricular Dysfunction in a Population at High Risk for Heart Failure. The PROBE-HF StudyJournal of Cardiac Failure, 2009
- Relation Between QRS Amplitude and Left Ventricular Mass in the Initial Stage of Exercise-Induced Left Ventricular Hypertrophy in RatsClinical and Experimental Hypertension, 2005
- Plasma Brain Natriuretic Peptide to Detect Preclinical Ventricular Systolic or Diastolic DysfunctionCirculation, 2004
- Correlation of Myocyte Lengthening to Chamber Dilation in the Spontaneously Hypertensive Heart Failure (SHHF) RatJournal of Molecular and Cellular Cardiology, 1998